Rhythm Historical Balance Sheet

RYTM Stock

USD 56.69 0.87 1.51%

Trend analysis of Rhythm Pharmaceuticals balance sheet accounts such as Property Plant And Equipment Net of 2.4 M, Accounts Payable of 4.4 M, Cash of 50.8 M or Non Current Assets Total of 29.6 M provides information on Rhythm Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Rhythm Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Rhythm Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Rhythm Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Rhythm Pharmaceuticals is a good buy for the upcoming year.

Rhythm Pharmaceuticals Inventory

10.41 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

About Rhythm Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Rhythm Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Rhythm Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Rhythm Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Rhythm currently owns. An asset can also be divided into two categories, current and non-current.

Rhythm Pharmaceuticals Balance Sheet Chart

At this time, Rhythm Pharmaceuticals' Other Stockholder Equity is very stable compared to the past year. As of the 16th of February 2025, Total Liabilities is likely to grow to about 196.8 M, while Property Plant And Equipment Net is likely to drop about 2.4 M.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net

Add Fundamental

Total Assets

Total assets refers to the total amount of Rhythm Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Rhythm Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Rhythm Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Rhythm Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Rhythm Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Rhythm Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.At this time, Rhythm Pharmaceuticals' Other Stockholder Equity is very stable compared to the past year. As of the 16th of February 2025, Total Liabilities is likely to grow to about 196.8 M, while Property Plant And Equipment Net is likely to drop about 2.4 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	32.9M	48.3M	55.5M	58.3M
Total Assets	382.5M	332.7M	382.7M	401.8M

Other Current Liab Total Assets

Rhythm Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Tangible Assets	Capital Surpluse	Current Deferred Revenue	Other Assets
Total Assets		0.82	0.91	0.88	0.72	-0.74	-0.9	0.75	0.79	0.87	0.81	0.94	0.79	0.42	0.94	0.44	0.9	0.92	0.64	0.88	0.94	0.47	0.94	0.97	0.15	0.79
Other Current Liab	0.82		0.97	0.5	0.38	-0.5	-0.94	0.32	0.54	0.96	0.96	0.65	0.67	0.51	0.66	0.75	0.63	0.94	0.89	0.83	0.67	0.47	0.64	0.92	-0.25	0.97
Total Current Liabilities	0.91	0.97		0.64	0.55	-0.56	-0.96	0.51	0.61	0.96	0.94	0.77	0.73	0.51	0.78	0.67	0.75	0.98	0.84	0.92	0.78	0.48	0.76	0.97	-0.13	0.94
Total Stockholder Equity	0.88	0.5	0.64		0.82	-0.77	-0.68	0.85	0.81	0.61	0.52	0.95	0.71	0.17	0.93	-0.02	0.9	0.69	0.22	0.69	0.94	0.42	0.95	0.77	0.48	0.46
Property Plant And Equipment Net	0.72	0.38	0.55	0.82		-0.74	-0.62	0.79	0.78	0.5	0.37	0.77	0.65	0.28	0.7	-0.04	0.86	0.67	0.17	0.76	0.75	0.36	0.77	0.69	0.46	0.35
Net Debt	-0.74	-0.5	-0.56	-0.77	-0.74		0.7	-0.53	-0.96	-0.63	-0.55	-0.76	-0.64	-0.23	-0.64	-0.12	-0.8	-0.69	-0.29	-0.61	-0.76	-0.49	-0.72	-0.73	-0.17	-0.52
Retained Earnings	-0.9	-0.94	-0.96	-0.68	-0.62	0.7		-0.51	-0.74	-0.95	-0.91	-0.81	-0.79	-0.55	-0.78	-0.63	-0.81	-0.98	-0.8	-0.91	-0.83	-0.52	-0.79	-0.97	0.09	-0.92
Accounts Payable	0.75	0.32	0.51	0.85	0.79	-0.53	-0.51		0.61	0.39	0.28	0.82	0.58	0.3	0.83	0.01	0.8	0.55	0.19	0.66	0.81	0.23	0.85	0.62	0.49	0.25
Cash	0.79	0.54	0.61	0.81	0.78	-0.96	-0.74	0.61		0.66	0.57	0.83	0.71	0.37	0.7	0.19	0.86	0.73	0.36	0.67	0.83	0.35	0.78	0.77	0.21	0.55
Non Current Assets Total	0.87	0.96	0.96	0.61	0.5	-0.63	-0.95	0.39	0.66		0.99	0.74	0.7	0.51	0.73	0.68	0.74	0.96	0.83	0.82	0.76	0.51	0.7	0.94	-0.24	0.98
Non Currrent Assets Other	0.81	0.96	0.94	0.52	0.37	-0.55	-0.91	0.28	0.57	0.99		0.66	0.64	0.49	0.66	0.72	0.65	0.91	0.86	0.75	0.68	0.49	0.62	0.89	-0.34	0.99
Cash And Short Term Investments	0.94	0.65	0.77	0.95	0.77	-0.76	-0.81	0.82	0.83	0.74	0.66		0.82	0.41	0.98	0.24	0.95	0.8	0.45	0.77	1.0	0.47	0.99	0.87	0.28	0.63
Common Stock Total Equity	0.79	0.67	0.73	0.71	0.65	-0.64	-0.79	0.58	0.71	0.7	0.64	0.82		0.5	0.79	0.4	0.79	0.76	0.55	0.73	0.83	0.65	0.81	0.79	0.12	0.63
Common Stock Shares Outstanding	0.42	0.51	0.51	0.17	0.28	-0.23	-0.55	0.3	0.37	0.51	0.49	0.41	0.5		0.38	0.69	0.54	0.51	0.69	0.45	0.44	0.08	0.39	0.49	-0.4	0.55
Short Term Investments	0.94	0.66	0.78	0.93	0.7	-0.64	-0.78	0.83	0.7	0.73	0.66	0.98	0.79	0.38		0.26	0.9	0.79	0.47	0.77	0.98	0.48	0.98	0.85	0.27	0.63
Non Current Liabilities Total	0.44	0.75	0.67	-0.02	-0.04	-0.12	-0.63	0.01	0.19	0.68	0.72	0.24	0.4	0.69	0.26		0.23	0.61	0.96	0.5	0.27	0.21	0.22	0.56	-0.62	0.78
Other Current Assets	0.9	0.63	0.75	0.9	0.86	-0.8	-0.81	0.8	0.86	0.74	0.65	0.95	0.79	0.54	0.9	0.23		0.82	0.44	0.79	0.95	0.44	0.94	0.86	0.22	0.63
Other Stockholder Equity	0.92	0.94	0.98	0.69	0.67	-0.69	-0.98	0.55	0.73	0.96	0.91	0.8	0.76	0.51	0.79	0.61	0.82		0.79	0.95	0.82	0.52	0.79	0.99	-0.07	0.91
Total Liab	0.64	0.89	0.84	0.22	0.17	-0.29	-0.8	0.19	0.36	0.83	0.86	0.45	0.55	0.69	0.47	0.96	0.44	0.79		0.69	0.48	0.33	0.43	0.75	-0.5	0.9
Property Plant And Equipment Gross	0.88	0.83	0.92	0.69	0.76	-0.61	-0.91	0.66	0.67	0.82	0.75	0.77	0.73	0.45	0.77	0.5	0.79	0.95	0.69		0.78	0.47	0.79	0.93	0.11	0.76
Total Current Assets	0.94	0.67	0.78	0.94	0.75	-0.76	-0.83	0.81	0.83	0.76	0.68	1.0	0.83	0.44	0.98	0.27	0.95	0.82	0.48	0.78		0.48	0.99	0.88	0.25	0.65
Common Stock	0.47	0.47	0.48	0.42	0.36	-0.49	-0.52	0.23	0.35	0.51	0.49	0.47	0.65	0.08	0.48	0.21	0.44	0.52	0.33	0.47	0.48		0.49	0.52	-0.09	0.47
Net Tangible Assets	0.94	0.64	0.76	0.95	0.77	-0.72	-0.79	0.85	0.78	0.7	0.62	0.99	0.81	0.39	0.98	0.22	0.94	0.79	0.43	0.79	0.99	0.49		0.86	0.32	0.59
Capital Surpluse	0.97	0.92	0.97	0.77	0.69	-0.73	-0.97	0.62	0.77	0.94	0.89	0.87	0.79	0.49	0.85	0.56	0.86	0.99	0.75	0.93	0.88	0.52	0.86		0.02	0.88
Current Deferred Revenue	0.15	-0.25	-0.13	0.48	0.46	-0.17	0.09	0.49	0.21	-0.24	-0.34	0.28	0.12	-0.4	0.27	-0.62	0.22	-0.07	-0.5	0.11	0.25	-0.09	0.32	0.02		-0.39
Other Assets	0.79	0.97	0.94	0.46	0.35	-0.52	-0.92	0.25	0.55	0.98	0.99	0.63	0.63	0.55	0.63	0.78	0.63	0.91	0.9	0.76	0.65	0.47	0.59	0.88	-0.39

Click cells to compare fundamentals

Rhythm Pharmaceuticals Account Relationship Matchups

Rhythm Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	187.1M	329.5M	382.5M	332.7M	382.7M	401.8M
Other Current Liab	12.0M	29.5M	32.9M	48.3M	55.5M	58.3M
Total Current Liabilities	18.0M	43.4M	39.8M	55.2M	63.5M	66.7M
Total Stockholder Equity	166.5M	284.2M	264.3M	169.8M	195.2M	137.7M
Property Plant And Equipment Net	5.0M	4.3M	3.4M	2.1M	2.4M	2.4M
Net Debt	(97.8M)	(56.7M)	(125.7M)	(58.8M)	(52.9M)	(55.6M)
Retained Earnings	(459.3M)	(528.9M)	(710.1M)	(894.7M)	(805.3M)	(765.0M)
Accounts Payable	4.9M	5.7M	4.8M	4.9M	5.6M	4.4M
Cash	100.9M	59.2M	127.7M	60.1M	69.1M	50.8M
Non Current Assets Total	5.4M	21.1M	28.2M	24.5M	28.1M	29.6M
Cash And Short Term Investments	172.8M	294.9M	333.3M	275.8M	317.2M	169.6M
Common Stock Shares Outstanding	44.1M	49.6M	52.1M	57.7M	66.3M	39.3M
Short Term Investments	71.9M	235.6M	205.6M	215.8M	248.1M	142.5M
Liabilities And Stockholders Equity	187.1M	329.5M	382.5M	332.7M	382.7M	203.9M
Non Current Liabilities Total	2.6M	1.9M	78.4M	107.8M	124.0M	130.1M
Other Current Assets	8.9M	12.4M	11.8M	8.9M	10.3M	5.8M
Other Stockholder Equity	625.8M	813.0M	974.4M	1.1B	1.2B	1.3B
Total Liab	20.5M	45.4M	118.2M	163.0M	187.4M	196.8M
Property Plant And Equipment Gross	5.0M	4.3M	3.4M	6.2M	7.1M	7.5M
Total Current Assets	181.7M	308.4M	354.2M	308.3M	354.5M	178.6M
Accumulated Other Comprehensive Income	49K	(1K)	(92K)	134K	154.1K	161.8K
Net Tangible Assets	281.0M	166.5M	279.5M	256.4M	294.8M	163.0M
Capital Surpluse	606.3M	625.8M	813.0M	974.4M	1.1B	1.2B
Current Deferred Revenue	12.4M	7M	1.4M	1.3M	1.2M	1.1M
Other Assets	403K	2.2M	12.1M	17.0M	19.5M	20.5M
Short Term Debt	1.1M	1.2M	684K	770K	693K	1.0M
Property Plant Equipment	5.7M	3.2M	2.8M	2.2M	2.5M	2.3M
Retained Earnings Total Equity	(325.3M)	(459.3M)	(528.9M)	(710.1M)	(639.1M)	(607.1M)
Net Invested Capital	166.5M	284.2M	264.3M	169.8M	195.2M	244.6M
Net Working Capital	163.7M	265.0M	314.4M	253.1M	291.0M	261.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Rhythm Pharmaceuticals is a strong investment it is important to analyze Rhythm Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rhythm Pharmaceuticals' future performance. For an informed investment choice regarding Rhythm Stock, refer to the following important reports:

How To Invest In Rhythm

Details

Is Rhythm Stock a good investment?

Details

What is Rhythm Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.32)

Revenue Per Share

1.863

Quarterly Revenue Growth

0.478

Return On Assets

(0.46)

Return On Equity

(1.48)

The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Rhythm Historical Balance Sheet

Rhythm Pharmaceuticals Inventory

10.41 Million

About Rhythm Balance Sheet Analysis

Rhythm Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Rhythm Pharmaceuticals balance sheet Correlations

Rhythm Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Rhythm Pharmaceuticals balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Other Assets	+ 0.99	Non Currrent Assets Other
Net Tangible Assets	+ 0.99	Cash And Short Term Investments
Capital Surpluse	+ 0.99	Other Stockholder Equity
Net Tangible Assets	+ 0.99	Total Current Assets

Other Stockholder Equity	- 0.98	Retained Earnings
Capital Surpluse	- 0.97	Retained Earnings
Cash	- 0.96	Net Debt
Retained Earnings	- 0.96	Total Current Liabilities
Non Current Assets Total	- 0.95	Retained Earnings
Retained Earnings	- 0.94	Other Current Liab